Scarica l'app Stockscreener
47.58
2.70%
-1.32
Dopo l'orario di chiusura:
47.58
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Trading Recap: Is Spyre Therapeutics Inc stock good for income investors2026 Pullback Review & Weekly Top Performers Watchlists - baoquankhu1.vn
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Spyre therapeutics CFO sells $370k in shares By Investing.com - Investing.com Australia
Sloan, Spyre Therapeutics CMO, sells $397k in shares By Investing.com - Investing.com Canada
Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows Sells 7,500 Shares - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Insider Sheldon Sloan Sells 7,958 Shares - MarketBeat
Turtle Cameron, Spyre Therapeutics CEO, sells $739k in shares By Investing.com - Investing.com Canada
Spyre Therapeutics (SYRE) CFO exercises options and sells 7,500 shares under 10b5-1 plan - Stock Titan
Spyre Therapeutics (SYRE) CEO sells 15,000 shares in planned trades - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Five new Spyre hires get stock options for 70,200 shares - Stock Titan
JPMorgan Chase & Co. Has $4.63 Million Stock Holdings in Spyre Therapeutics, Inc. $SYRE - marketbeat.com
Spyre Therapeutics, Inc. team assembles 1,500 kits for students during annual gathering - Traders Union
SYRE SEC FilingsSpyre Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year HighShould You Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Receives "Buy" Rating from BTIG Research - MarketBeat
SYRE Receives Reiteration of 'Buy' Rating by BTIG | SYRE Stock N - GuruFocus
SYRE Receives Reiteration of 'Buy' Rating by BTIG | SYRE Stock News - GuruFocus
BTIG reiterates Buy on Spyre stock after J&J deal validates approach - Investing.com Canada
Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy? - simplywall.st
Can Spyre Therapeutics Inc grow without external fundingEarnings Risk Report & Growth Focused Entry Reports - baoquankhu1.vn
Vanguard disaggregates holdings for Spyre Therapeutics (SYRE); reports 0 shares - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 5.7%Time to Buy? - MarketBeat
Spyre Therapeutics stock hits 52-week high at 45.79 USD By Investing.com - Investing.com Australia
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month HighHere's What Happened - marketbeat.com
Spyre Therapeutics stock hits 52-week high at 45.79 USD - Investing.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Assessing Spyre Therapeutics (SYRE) Valuation After Strong One Year Return And Premium Price To Book Ratio - Yahoo Finance
Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst - theglobeandmail.com
Spyre Therapeutics Completes First-in-Human Study of SPY001-001, De-risking Early Pipeline - TipRanks
US Market Recap: Can Spyre Therapeutics Inc lead its sector in growth - baoquankhu1.vn
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - AOL.com
VR Adviser Increases Spyre Therapeutics Investment to $120.74MNews and Statistics - IndexBox
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means - The Motley Fool
VR Adviser Increases Stake in Spyre Therapeutics by 1 Million Shares - Intellectia AI
Signal or Noise: How VR Adviser's Acquisition of Spyre Therapeutics Impacts Fools - Bitget
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools - The Motley Fool
SYRE Stock Gets a Boost: Stifel Raises Price Target to $92 | SYR - GuruFocus
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $92.00 - MarketBeat
Stifel raises Spyre stock price target to $92 on TL1A potential - Investing.com Canada
Guggenheim Sticks to Its Buy Rating for Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE) - Seeking Alpha
Spyre Therapeutics (SYRE) Is Up 7.3% After Accelerating SPY072 Phase 2 POC TimelineHas The Bull Case Changed? - simplywall.st
BTIG Reiterates Buy Rating for Spyre Therapeutics (SYRE) with $7 - GuruFocus
Spyre Therapeutics (SYRE) Advances RA Sub-Study with Early Resul - GuruFocus
Leerink Maintains Outperform on Spyre Therapeutics, Inc. (SYRE) March 16, 2026 - Meyka
Deutsche Bank Raises Price Target for Spyre Therapeutics on Strong Cash Position - timothysykes.com
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 9.3%Should You Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Given Buy Rating at BTIG Research - MarketBeat
Leerink reiterates Spyre stock Outperform on faster trial timeline By Investing.com - Investing.com Canada
Spyre Therapeutics stock remains top 2026 pick at Guggenheim By Investing.com - Investing.com Canada
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 - Bitget
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):